Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma

NCT03546582 is registered in ClinicalTrials.gov with RTOG Foundation, Inc. as lead sponsor.

NCT NCT03546582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03546582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Lead sponsor
RTOG Foundation, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 14, 2018
Completion date
July 31, 2029
Enrollment
86 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma (hnscc)